Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2016-05-30 | arimoclomol citrate | Orphazyme (Denmark) | inclusion body myositis |
Granting of the orphan status in the EU |
2016-05-30 | Fc- and CDR-modified humanised monoclonal antibody against C5 | Alexion Pharmaceuticals (USA - CT) | paroxysmal nocturnal hemoglobinuria (PNH) |
Granting of the orphan status in the EU |
2016-05-30 | (R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6- dihydrobenzo[h]quinazolin-2-amine dihydrochloride | Coté Orphan Consulting (UK) | biliary tract cancer |
Granting of the orphan status in the EU |
2016-05-30 | 4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide | Shire (UK - USA) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2016-05-30 | autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene | Fondazione Telethon (Italy) | beta thalassaemia intermedia and major |
Granting of the orphan status in the EU |
2016-05-30 | H-Phe-Ser-Arg-Tyr-Ala-Arg-OH-acetate | QRC Consultants (UK) | amyotrophic lateral sclerosis |
Granting of the orphan status in the EU |
2016-05-30 | pentosan polysulfate sodium | Nextrasearch di Gasparetto Adolfo (Italy) | interstitial cystitis | Granting of the orphan status in the EU |
2016-05-30 | polyethylene glycol modified recombinant C-terminal truncated human cystathionine beta-synthase | Alan Boyd Consultants (UK) | homocystinuria |
Granting of the orphan status in the EU |
2016-05-30 | recombinant adeno-associated viral vector containing the human RPGR gene | TMC Pharma Services (UK) | retinitis pigmentosa caused by mutations in the RPGR gene |
Granting of the orphan status in the EU |
2016-05-30 | rimiducid | QRC Consultants (UK) | graft-versus-host disease |
Granting of the orphan status in the EU |
2016-05-30 | vemurafenib | Groupe d’étude des histiocytoses (France) | Langerhans’ cell histiocytosis | Granting of the orphan status in the EU |
2016-05-30 | temsirolimus | Centro de Investigación Biomédica en Red (CIBER) (Spain) | adrenoleukodystrophy |
Granting of the orphan status in the EU |
2016-04-28 | bevacizumab and erlotinib | Roche (Switzerland) | first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations | Positive opinion for the granting of a Market Authorisation in the EU |
2016-09-23 | canakinumab | Novartis (Switzerland) | periodic fever syndromes/hereditary periodic fevers (tumor necrosis factor-receptor associated periodic syndrome (TRAPS) and hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF) not adequately controlled with colchicine) |
Granting of a Market Authorisation in the US |
2017-04-28 | nivolumab | BMS (USA - NY) | recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy | Granting of a Market Authorisation in the EU |
2016-04-29 | pimavanserin | Acadia Pharmaceuticals (USA - CA) | psychosis associated with Parkinson’s disease |
Granting of a Market Authorisation in the US |
2013-01-08 | Bind Biosciences (USA - MA) | Granting of a patent | ||
2016-04-06 | automated diagnostics system | Theradiag (France) | Product launch | |
2016-06-16 | monitoring test of vedolizumab | Theradiag (France) | Crohn disease ulcerative colitis |
Product launch |
2016-05-19 | adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene | Genable Technologies (Ireland) | retinitis pigmentosa |
Granting of a patent |
© 2024 Biopharmanalyses - Powered by Samacom+